Suzhou Kangheshun Medical Technology Co., Ltd was founded with a mission to provide innovative Point-of-Care Testing (POCT) immunoassay solutions that are reliable, portable, safe and convenient to use and it can generate results within minutes.
Our founders have served in the world' s leading diagnostic and biotech companies for many years in critical technical and business roles. We combine advanced understanding of immunoassays principles, relevant experience, rigorous quality control, and operational efficiencies to provide innovative, high quality and cost-effective diagnostic products worldwide.
We are the first and only company to commercialize true single-reagent immunoturbidometric tests that can be conducted by a palm-sized automated instrument with accuracies comparable automated platforms typically installed in central testing labs.
this technology only requires a fraction of a drop of blood taken from a patient' s fingertip. the blood sample is then injected into a reaction vial pre-filled with test specific reagent. The test results are than available within two minutes of blood collection. The technology is also compatible with serum or plasma samples, and is extremely suitable for use in doctors' offices, intensive care units, clinical labs or other points of care settings.
Our efforts are focused on the diagnoses of various inflammations that can be caused by infections of viruses, bacteria, fungi, autoimmune diseases, etc. Our products can be utilized to identify inflammation in specific organs, such as lungs and kidneys, as related to whole body. One of the tests in our pipelines can be potentially used to diagnose and evaluate lung damage caused by COVID-19. The test could potentially be an alternative to CT' s in a Point-of Care setting to confirm COVID-19 with greater convenience and reduce workloads and expenses for healthcare systems.
We recently developed serological tests for SARS-Cov-2 IgG and IgM Rapid Test Cassette, which can be an efficient supplement to current nucleic acid tests. The test can identify a positive case within a couple minutes and report the final results within 15 minutes. The test has received CE mark certificate. FDA has allowed the test cassettes to be sold to clinical labs in the United States. One of the leading US clinical labs has evaluated our test cassettes, and the results shows a > 84% agreement in positive cases and > 86.2% agreement in negative cases when compared with Abbott nucleic acid test.
Suzhou Kangheshun Medical Technology Co., Ltd also provides US based customer service to directly support our customers and end users in both North America and South America.